SNTI: Senti Biosciences, Inc. Stock

by  •  • Comments Off on SNTI: Senti Biosciences, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 16.87
Enterprise Value ($M) -19.06
Book Value ($M) 66.91
Book Value / Share 1.46
Price / Book 0.25
NCAV ($M) 18.63
NCAV / Share 0.41
Price / NCAV 0.91

Profitability (mra)
Return on Invested Capital (ROIC) -0.68
Return on Assets (ROA) -0.44
Return on Equity (ROE) -0.63

Liquidity (mrq)
Quick Ratio 5.62
Current Ratio 5.62

Balance Sheet (mrq) ($M)
Current Assets 71.20
Assets 119.48
Liabilities 52.57
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 2.56
Operating Income -64.44
Net Income -71.06

Cash Flow Statement (mra) ($M)
Cash From Operations -52.40
Cash from Investing 30.08
Cash from Financing 0.78

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-04-26 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No.1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRAN
2024-03-21 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PUR
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PUR
2023-08-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUAN

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-03 4,188 56,364 7.43
2024-05-02 18,074 19,226 94.01
2024-05-01 54,902 27,359 200.67
2024-04-30 377,590 285,342 132.33
2024-04-29 26,607 3,138 847.90

(click for more detail)

Similar Companies
SNGX – Soligenix, Inc. SNOA – Sonoma Pharmaceuticals, Inc.
SNPX – Synaptogenix, Inc. SONN – Sonnet BioTherapeutics Holdings, Inc.
SPRC – SciSparc Ltd.


Financial data and stock pages provided by
Fintel.io